Multicenter, Open-label Study to Evaluate the Safety and Efficacy (by Blinded Reading) of Contrast-Enhanced Magnetic Resonance Angiography (MRA) After a Single Intravenous Injection of 0.1 mmol/kg Gadobutrol in Subjects With Known or Suspected Vascular Disease of the Supra-aortic Vessels
Latest Information Update: 12 Jul 2019
At a glance
- Drugs Gadobutrol (Primary)
- Indications Carotid stenosis; Renal Artery Obstruction; Vascular disorders
- Focus Diagnostic use; Registrational
- Acronyms GEMSAV
- Sponsors Bayer; Bayer HealthCare
- 12 Jul 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
- 06 May 2016 New trial record
- 29 Apr 2016 Primary endpoint has been met. (Specificity for Exclusion of Clinically Significant Disease Using Gadobutrol-Enhanced MRA and Unenhanced MRA)